aid: dem-bio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/dem-bio.png
name: DEM Bio
description: 'DEM BioPharma is a Cambridge, Massachusetts biotechnology company developing first-in-class
  cancer therapeutics that target the signals solid tumors use to evade immune destruction. The company
  pioneers next-generation macrophage and innate-immune immunotherapies discovered through its proprietary
  CHoMP (Co-culture with Human Myeloid Phagocytes) functional-genomics platform, which uses CRISPR-based
  screening to identify novel "don''t-eat-me" and activating targets on myeloid cells. DEM launched in
  2022 with $70M in Series A financing and is backed by Longwood Fund, Emerson Collective, Pfizer Ventures,
  Astellas, and Insight Partners. Added to the API Evangelist network as a portfolio-company profile; DEM
  publishes no public developer or API surface at this time.'
url: https://raw.githubusercontent.com/api-evangelist/dem-bio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- insight-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biotech Therapeutics
- Oncology
- Immunotherapy
- Cancer
- CRISPR
- Drug Discovery
- Functional Genomics
- Macrophage
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/dem-bio-domain-security.yml
- type: Website
  url: https://dembiopharma.com/
- type: Blog
  url: https://dembiopharma.com/news.html
- type: Support
  url: https://dembiopharma.com/contact.html
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence